EG 201
Alternative Names: EG-201Latest Information Update: 15 Oct 2024
Price :
$50 *
At a glance
- Originator Evergreen Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Wet age-related macular degeneration
Most Recent Events
- 10 Oct 2024 Preclinical trials in Wet age-related macular degeneration in USA (Ophthalmic) prior to October 2024 (Evergreen Therapeutics pipeline, October 2024)
- 02 Jan 2023 EG Pharm plans to file IND for EG 201 in Wet-age related macular degeneration (EG Pharm website, December 2022)
- 23 Dec 2022 Evergreen Therapeutics files IND to initiate clinical trial in Wet-age related macular degeneration prior to December 2022 (Evergreen Therapeutics website, December 2022)